The GATA-1 gene is VCFS may require major surgery for their anomalies and this carrier located on the X-chromosome and encodes GATA-1 protein discount celebrex 100mg without prescription arthritis medication arcoxia, which state may increase the bleeding risk buy celebrex 200mg line arthritis detox diet inflammation. GATA-1 plays an important role in the development erythroid and megakaryocytic Glanzmann thrombasthenia cells cheap celebrex 100mg overnight delivery arthritis ketogenic diet. Several mutations have been described in GATA-1, resulting GT is an autosomal-recessive bleeding disorder characterized by a in platelet abnormalities (dysmegakaryopoiesis, thrombocytopenia, defective platelet integrin IIb 3 receptor. The integrin IIb 3 (GP large or small platelets, -granule deﬁciency) and dyserythropoietic IIb-IIIa) receptor is abundantly expressed on platelets: 80 000 anemia with different clinical severity. Increased hemoglobin A2, copies are found on the surface of each platelet. The receptor is a persistence of hemoglobin F, and unbalanced production of - and heterodimer consisting of IIb and 3 subunits found in an inactive -globulin synthesis may cause a “beta-thalassemia-like pheno- state in resting platelets. After platelet activation, inside-out signal- type” in some patients. It has been shown to be associated with the development of 8. Recommendations for acute megakaryoblastic leukemia and transient myeloproliferative the standardization of light transmission aggregometry: a disorder in patients with Down syndrome. Published Familial platelet disorder with propensity to myeloid malig- online ahead of print April 10, 2013. Familial platelet disorder with propensity to myeloid 9. Glycoprotein analysis for the diagnostic evaluation malignancy is an autosomal-dominant disorder characterized by of platelet disorders. Hematopoietic stem cell transplantation using a with platelet traits and platelet disorders. Semin Thromb sibling known to be negative for RUNX1 mutations is the only Haemost. Watson SP, Lowe GC, Lordkipanidze M, Morgan NY; GAPP consortium. Genotyping and phenotyping of platelet function Wiskott-Aldrich syndrome. Inherited disorders of platelets: protein gene (WASp) mutations. WAS protein regulates actin membrane glycoprotein disorders. Hematol Oncol Clin North ﬁlament reorganization in hematopoietic cells and regulates lympho- Am. Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, different phenotypes: WAS, X-linked thrombocytopenia, and X- Valentino L. Desmoppressin (DDAVP) in the management of linked neutropenia. The classic or severe WAS is characterized by patients with congenital bleeding disorders. In microthrombocytopenia, eczema, and susceptibilities to infections, press. Currently, the only curative therapy is the improves recruitment of activated platelets to collagen but allogeneic hematopoietic stem cell transplantation if a matched simultaneously increases platelet endothelial interactions in donor is available. Thrombopoietin and hematopoietic Conﬂict-of-interest disclosure: The author declares no competing stem cell. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Reyhan Diz-Ku¨çu¨kkaya, MD, Istanbul Bilim University, Avrupa 18. Advances in the understanding Florence Nightingale Hospital, Hematology-Oncology Clinic, Bed- of congenital amegakaryocytic thrombocytopenia. Br J Haema- rettin mahallesi, Bedii Gorbon sokak, No. Beyog˘lu, Istanbul,˙ Turkey; Phone: 90 212 224 4950; Fax: 90 19. Two patterns of 212 315 3640; e-mail: rkucukkaya@hotmail. Molecular pathogenesis and clinical Gruppo di Studio delle Piastrine. Peitsidis P, Datta T, Paﬁlis I, Otomewo O, Tuddenham EG, related disorders. Bernard Soulier syndrome in pregnancy: a system- 276. Platelet integrin IIb 3: activation pound heterozygosity for 2 novel TMEM16F mutations in a mechanisms. Inherited platelet function disorders: overview and odyssey: a technology-driven saga of a receptor with twists, disorders of granules, secretion, and signal transduction. Stormorken H, Sjaastad O, Langslet A, Sulg I, Egge K, bashenia: a review of ITGA2B and ITGB3 defects with Diderichsen J. A new syndrome: thrombocytopathia, muscle emphasis on variants, phenotypic variability, and mouse mod- fatigue, asplenia, miosis, migraine, dyslexia and ichthyosis. Current strategies in diagnosis of state of art and future directions. Molecular determi- b3 integrins are osteosclerotic because of dysfunctional oste- nants of platelet delta storage pool deﬁciencies: an update. Quebec exon 6 of human GP6 generates a truncated protein associated platelet disorder: update on pathogenesis, diagnosis, and treat- with a bleeding disorder in 4 Chilean families. Inherited thrombocytopenia due to a GATA-1 mutations. Lo´pez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, 34. Congenital erythropoietic porphyria due to a XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. Acute megakaryoblastic disease update: the disease, the molecule and the animal model. Five new pedigrees with Willebrand disease (VWD) from Type 2B VWD using a inherited RUNX1 mutations causing familial platelet disorder simpliﬁed ristocetin-induced-platelet-agglutination mixing as- with propensity to myeloid malignancy. With the increased availability of safe clotting factor concentrates, the primary focus in clinical management is now the prevention of long-term complications, most notably the debilitating hemophilic arthropathy that is associated with severe disease. This article reviews evidence-based approaches for managing both children and adults with hemophilia. Deﬁnitive evidence of improved clinical results from primary prophylaxis started in young patients with severe hemophilia A and a minimal bleeding history is presented. Furthermore, recent studies showing beneﬁts for initiating prophylaxis in older adolescents and adults with established joint disease are examined.
RCT purchase celebrex cheap online arthritis diet nhs, Multinational - CIC HFA- Yes (low) Overall AEs(%):38% of Fair 23 2007 DB celebrex 100mg arthritis management dogs, DD Australia buy generic celebrex canada acute bacterial arthritis definition, MDI (160) patients (n=158 in G1, Germany, vs. RCT, Multinational (13 FP MDI No (high Overall AEs: NR Fair 25 1995 DB, DD countries (1000) vs high vs worldwide) vs medium) Withdrawals due to AEs: 671 FP MDI NR Age 18-70, (2000) 6 weeks severe, on ICS, vs Overall adverse events smokers BUD MDI (%): 61 vs 49 vs 51 excluded (1600) Oral candidiasis- Multicenter (66) thrush (%): 3 vs 4 vs 5 Cough (%): 3 vs 6 vs 5 Sore throat (%): 4 vs 4 vs 2 Headache (%): 5 vs 7 vs 6 Upper respiratory tract infection (%): 11 vs 10 vs 6 Respiratory infection (%): 4 vs 1 vs 2 Rhinitis (%): 4 vs 1 vs 3 Hoarseness (%): 6 vs 3 vs 3 Ferguson et al. RCT, Multinational (6 FP DPI (400) Yes Overall AEs(%): NR Fair 26 1999 DB, DD countries vs. RCT, Multinational FP DPI No (both Overall AEs(%): 78 vs. Fair 27 1999 DB, DD (Belgium, (2000) are high 77 Canada, vs. RCT, Multinational (4: FP DPI (400) No Overall AEs(%): 63 vs. RCT Finland BUD DPI Yes Overall AEs: NR Fair 29 2000 (800 for 2 75 Age 5-15, months, then Steroid Withdrawals due to AEs severity NR, new 400) dosing (%): NR 6 months onset of asthma vs. RCT, France BDP MDI Yes (all Overall AEs(%): 38 vs Fair 1 2005 open- (800) high) 35 vs 37, P = 0. RCT, Multinational FP DPI (800) Yes (high) Overall AEs(%): 61. RCT, Multinational (17) Mometasone No (only Overall AEs: NR Fair 31 2000 single- DPI (200) for MF blind Age ≥ 12, vs 400 vs. Withdrawals due to AEs moderate, on Mometasone BUD, (%): 730 ICS, smokers DPI (400) both 3 vs < 1 vs 2 vs 4 vs 2 excluded vs medium) 12 Mometasone Dysphonia (%): weeks Multicenter (57) DPI (800) 4. Oral candidiasis was uncommon in this study, reported by only 16 patients overall, and had a similar incidence among the treatment groups (N = 4, 6, 4, and 3) Corren et al RCT, US Mometasone No Overall AEs(%): 8 vs 9 Fair 32 2003 DB, DD DPI (400) (medium vs 8 Controller medications for asthma 354 of 369 Final Update 1 Report Drug Effectiveness Review Project Study Comparison design Country (total daily N Population dose in Equivale Quality Study Duration Setting mcg) nt dosing Results rating Age ≥12, vs vs. There was only one report of oral candidiasis in one MF-reated patient. Fair 33 2004 (mean dose average 86 945 Age ≥18, mild to at start and both are severe, smoking end: 941. Ciclesonide compared with flunisolide No systematic reviews or head-to-head trials found Ciclesonide compared with fluticasone Bateman RCT Multinational - CIC HFA- Yes (high) Overall AEs (N): 373 vs. Fair 34 2008 Europe, North MDI (640) 401 528 America, South vs. Africa FP HFA-MDI Withdrawals due to AEs 6 months (660) (%): NR Age 12-75, moderate to Oral candidiasis- severe, on ICS, thrush (%): 2. Hungary, South FP DPI (400) Withdrawals due to AEs 12 Africa, Spain (%): 1. Netherlands, FP HFA-MDI Withdrawals due to AEs 12 Spainn, Hungary, (176) (%): 2. Fair DB, DD Austria, Canada, MDI (80) 43 Germany, vs. G4: 32/41 weeks NR CIC HFA- MDI (640) Withdrawals due to AEs Multicenter vs. G4: Controller medications for asthma 357 of 369 Final Update 1 Report Drug Effectiveness Review Project Study Comparison design Country (total daily N Population dose in Equivale Quality Study Duration Setting mcg) nt dosing Results rating 3/41 Magnussen RCT Multinational - CIC HFA- Yes (low) Overall AEs(%): 25. Republic, France, CIC HFA- Withdrawals due to AEs 12 Italy, The MDI (160) (n): 3 vs. Slovakia, Spain FP HFA-MDI Oral candidiasis- thrush, (176) cough, sore throat, Age >12, mild to headache, or severe, 21-24% hoarseness (%): NR ex- and current smokers Upper respiratory tract infection (%): Reported Multicenter similar %s for the three groups (from 0. Portugal, South CIC HFA- Withdrawals due to AEs 12 Africa MDI (160) (%): 5. Age 6-11, mild to FP HFA-MDI Oral candidiasis- severe, smoking (176) thrush (%): 0 vs. Age 6-15, mild to FP HFA-MDI Withdrawals due to AEs 12 severe, excluded (176) (n): 0 vs. RCT, DB Multi-national MF DPI (200) No (only Overall AEs (%): Fair 43 2001 (20) vs for 20 vs 26 vs 30 vs 29 733 MF DPI (400) medium Age ≥12, vs doses of Withdrawals due to AEs 12 moderate, on MF DPI (800) each: MF (%): weeks ICS, excluded vs 400 vs. RCT, US FP MDI (196) Yes Overall AEs(%): Fair 44 1999 DB, + Salmeterol (medium Drug-related: 14 vs 13 triple- Age ≥12, not (84) vs for both vs 8 dummy controlled on FP MDI (440) ICS-only ICS, excluded vs arms) Withdrawals due to AEs 680 smokers TAA MDI (%): (1200) 4 vs 1 vs 2 12 Multicenter, weeks Pulmonary/allerg Oral candidiasis- y medicine clinics thrush (%): (50) 2 vs 2 vs 1 Dysphonia (%): 3 vs 4 vs < 1 Sore throat (%): 3 vs < 1 vs 2 Condemi et al. RCT, US FP DPI (500) No Overall AEs(%): Fair 45 1997 DB, DD vs (medium 15 vs 8 vs 13, P = 0. RCT, US FP DPI (500) No Overall AEs (%): Fair 46 1998 DB, DD vs (medium 20 vs 5 vs 5, P < 0. Molimard M, Martinat Y, Rogeaux Y, Moyse D, Pello JY, Giraud V. Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Lorentzen KA, Van Helmond JL, Bauer K, Langaker KE, Bonifazi F, Harris TA. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler. Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. Medici TC, Grebski E, Hacki M, Ruegsegger P, Maden C, Efthimiou J. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects. Controller medications for asthma 360 of 369 Final Update 1 Report Drug Effectiveness Review Project 14. Raphael GD, Lanier RQ, Baker J, Edwards L, Rickard K, Lincourt WR. A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma.
Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r celebrex 200mg with amex rheumatoid arthritis in your neck, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year generic celebrex 200 mg mastercard arthritis in back and yoga, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria Langrick N o/N R N o N otreported F air N R/N R/69 P regnantorbreastfeeding buy celebrex 200 mg visa arthritis shoes,currentrespiratorytract 1984 infection ornasal abnorm alities,received system ic steroid England therapywithin the previous3m onthsoranti-allergy treatm entwithin the previousweek were noteligible. Ratner N o/N R N o Yes68ptsfrom F air 256/N R/218 U ncooperative orunable tocom plywith study 1996 one testing requirem ents,used nasal corticosteroidsornasal crom olyn U S A centerdue to sodium within 2week sofsystem ic corticosteroidswithin 4 low pollen count week sbefore random iz ation,had a total sym ptom severity and inabilityto score oflessthan 2orgreaterthan 7atrandom iz ation visit, show superior were asthm atic and required chronic bronchodilator efficacy therapy,orhad a historyorpresence ofclinicallysignificant m edical disorderthateitherwould have com prom ised the studyresultsorhave been detrim ental tothe patient W elsh N o N o N o F air N R/N R/120 N otspecificallylisted asexclusion criteria,however,pts 1987 were included iftheydid nothave nasal polyps,were not U S A pregnantorlactating,had good general health without illnessthatinterfere with the study NCS Page 92 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Greenbaum Methodsnot N otreported U nk nown: Yes DBbutm ethodsnot N /A DBbutm ethods Yes 1988 specified dem ographics specified notspecified Yes Canada notgiven but N o textindicates N o the groupsare "well balanced" NCS Page 94 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria S tern N o/N R Authorsreport N o F air N R/N R/635 H ad significantsym ptom sofsignsrelated tothe nose other 1997 doing an "all than those ofseasonal allergic rhinitis(perennial or U K,Denm ark patientstreated" atrophic rhinitis),anyobstructive structural abnorm alityin analysisand stated the nose,ornasal polyps. Acute orchronic infectious itwasnotdifferent sinusitisand iftheyhad experienced significantupper from the other respiratorytractinfection in the 2week spreceding the analysis. P tsusing topical nasal corticosteroid therapyduring resultswere not 1m onth before the studyorsystem ic corticosteroidsin the given asnum erical 2m onthspreceding the studywere excluded,aswere data only patientswhohad im m unotherapyforseasonal allergic description in the rhinitisin the 2yearspreceding the studyorastem iz ole text. Greenbaum N o/N R N o N o F air- N R/N R/122 <12yo,had k nown hypersensitivitytocorticosteroids, 1988 dem ographics including flunisolide;had active quiescenttuberculosisof Canada notgiven the respiratorytractoruntreated fungal,bacterial,or therefore results system ic viral infectionsorocularherpessim plex,orthose cannotbe with unhealed nasal ulcers,surgeryortraum a;had any reproduced. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance S tern Run-in:N o N o Yes Grantfrom Astra 1997 W ash-out:N o DracoAB U K,Denm ark Greenbaum Run-in:N R N o Yes N otclearlyreported,Dem ographics 1988 W ash-out:N R however,requestfor notgiven Canada reprintstoAuthor from S yntex,Inc. NCS Page 96 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria H ebert N o/N R N o N o F air N R/N R/501 Asthm a requiring therapywith inhaled orsystem ic 1996 corticosteroids,crom oglycate,ornedocrom il;were k nown tobe unresponsive tonasal corticosteroids;were dependenton system ic corticosteroidsornasal decongestants;had an allergytocorticosteroids;orhad received potentcorticosteroid treatm entwithin the last m onth. Chronic m edication ora significantm edical condition which could interfere with the study;asthenia or grossobesity;clinicallyrelevantabnorm al laboratorytests, vital signs,orelectrocardiogram ;patientson im m unotherapy(unlesson a stable regim en foratleast6 m os. Certain concom itantm edicationswere restricted during the study,including corticosteroids(exceptforlow-potency topical preparationssuch as hydrocortisone),m astcell stabiliz ers, antihistam ines(apartfrom rescue loratadine),decongestants,aspirin, nonsteroidal anti-inflam m atorydrugs, and system ic antibiotics. NCS Page 98 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance H ebert Run-in:N o N o Yes N otspecifically 8. NCS Page 99 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria Lum ry N o/N R N o N o F air N R/N R/152 Clinical evidence ofanysignificantphysical abnorm alities 2003 orabnorm al laboratoryvalues;nasal candidiasis,acute or U S A chronic sinusitis,significantnasal polyposisorothergross anatom ical deform ityofthe nose sufficienttoim pairnasal breathing;concurrentm edical conditionslik elytointerfer with the course ofthe study;use ofsystem ic corticosteroids in the previous42daysornasal orinhaled corticosteroids in the previous30days;use ofnasal crom olyn sodium in the previous28daysorastem iz ole in the previous60days; treatm entwith an investigational drug within 60days; com m encem entofim m unotherapywithin the previoussix m onths;use ofm edication forotherm edical conditionsthat m ightproduce orrelieve the signsand sym ptom sofallergic rhinitisforsixdayspriortoand throughoutthe treatm ent period;and pregnancy,lactation,orinadequate contraceptive precautionsin fem alesofchild-bearing potential NCS Page 101 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance Lum ry Run-in:N o N o Yes Aventis 2003 W ash-out:Yesx P harm aceuticals, U S A 6days role notspecified NCS Page 102 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria S m all N o/N R N o,efficacyn=223 N o F air N R/N R/233 W om en whowere pregnantorofchildbearing potential and 1997 and safetyn=233 notpracticiing approved m ethod ofbirth control;P tm eeting Canada atleastone ofthe following criteria were excluded:a clinicallysignificant,renal,hepatic,cardiac,respiratory (including asthm a),neurologic,collagen-vascular,or psychiatric disorder;cancer;untreated fungal,bacterial,or viral infections;nasal septal ulcerorperforation;nasal surgeryortraum a;physical nasal obstruction greaterthan 50%;a historyofhabitual abuse ofnasal decongestants; use ofanysystem ic,nasal,inhaled corticosteroidswithin 30daysofscreening visit;use ofnasal sodium crom oglycate,anticholinergics,vasoconstrictors,or antihistam ines(exceptastem iz ole)within 7daysofthe screening visit;use ofastem iz ole within 60daysofthe screening visit;use oftopical,oral orboth typesof decongestantsm ore than three tim esperweek forthe previous3m onths(90days):cardiovasculardrugs, horm ones,neurolepticsoranyotherdrugsthatcan cause, suppress,orexacerbate the sym ptom sofallergic rhinits; im m unotherapyunless on a m aintenance regim en atthe tim e ofscreening; historyofhypersensitivityornonresponse to corticosteroids;and participation in another investigational studywithin 30daysofthe screening visit. S teroidswere notperm itted,exceptfororal contraceptivesand estrogen replacem enttherapy. NCS Page 104 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance S m all Run-in:N o N o Yes Grantfrom Rhone- Race not 1997 W ash-out:yesx P oulene Rorer reported,M/F Canada 5-14days Canada,Inc. O ne equal authorfrom this age range 12-70 source aswell W ide varietyof allergensdue to m ulticenter, P ollen countnot reported. N otIT T ,single blind k eepsfrom being rated good NCS Page 105 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Rep o rtingo f attritio n, cro s s o v ers , Au tho r, Allo catio n Eligibility Ou tco me Care adherence,and Year, Rando miz- co ncealment Gro u p s s imilarcriteria as s es s o rs p ro v ider co ntam- Co u ntry atio nadequ ate? Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Au tho r, Lo s s to fo llo w- Po s t-rando m- Nu mbers creened/ Year, u p :differential/ Intentio n-to -treat izatio n eligible/ Co u ntry high (ITT)analys is exclu s io ns Qu ality rating enro lled Exclu s io ncriteria LaF orce N o/N R N otclear,num bers N o F air-good N R/N R/238 Being treated with corticosteroidsorintranasal sodium 1994 notreported in crom olyn,required inhaled orsystem ic corticosteroid U S A resultsbutonly3 therapyforongoing asthm a,had an upperrespiratorytract outof238patients infection,oriftheywere scheduled toaltertheir withdrew from im m unotherapyregim en during the study,wom en atrisk of study pregnancy(postm enarchal orprem enopausal wom en and those notusing oral contraceptives)and patientswith any significantm edical disorderorim paired adrenal function as indicated byclinical laboratorytests. Bronsk y U nk nown N otclear,authors N o F air N R/N R/161 P regnancyorlactation,nasal polyps,sinusitis,significant 1987 reportthatof322 septal deviation,oranyothernasal disease;historyof U S A f/uvisits13were alcohol ordrug abuse;m ental im pairm ent;asthm a m issed com pletely, requiring corticosteroid therapyorsensitivitytoinhaled 30were outside the corticosteroid therapyorsensitivitytoinhaled appropriate corticosteroids;im m unotherapyforallergic rhinitisin the schedule. N o m onth priortothe trial;adm inistration ofanyinvestigational m ention ofm ade if drug within 30days,orcorticosteroid orcrom olyn sodium thisdata from within twoweek s,orantihistam ineswithin 24hourspriorto these ptswas the initiation ofthe trial. Qu ality as s es s ment o f head-to -headtrials inp atients withSAR Clas s Co ntro l Au tho r, naïv e gro u p Year, Ru n-in/ p atients s tandardo f Co u ntry Was ho u t o nly care Fu nding Relev ance LaF orce Run-in:Yes N o Yes Grantfrom Glaxo, 1994 W ashout:N o Inc. U S A Bronsk y Run-in:N o N o Yes N otdirectlystated 12-65yo 1987 W ash-out:N o butone authoris Multicenter,U S A U S A affiliated with Glaxo,M=F Inc. O r lactating Race included NCS Page 108 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR InternalValidity Rep o rtingo f attritio n, Lo s s to Au tho r, Allo catio n Gro u p s Eligibility Ou tco me cro s s o v ers , fo llo w-u p : Year, Rando mizatio n co ncealment s imilarat criteria as s es s o rs Carep ro v iderPatient adherence,and differential/ Co u ntry adequ ate? Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR External Validity Nu mber Clas s Co ntro l Au tho r, Intentio n-to -Po s t- s creened/ naïv e gro u p Year, treat (ITT) rando mizatio n Qu ality eligible/ Ru n-in/ p atients s tandard Co u ntry analys is exclu s io ns rating enro lled Exclu s io ncriteria Was ho u t o nly o f care Ratne r ye s no fair NR/NR/726 Clinic allysignific c antabnorm allabte st1we e k no ye s 2006a re sultsor physic alfind ingsof nasal base line run-in U S polypsor nasaltrac tm alform ations; e vid e nc e of oc ular he rpe ssim ple xor c atarac tsor historyof glauc om a; e vid e nc e of abronc hial,pulm onaryor RT Ior d iord e rsothe r than ARor asthm aw. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Au tho r, Year, Co u ntry Fu nding Relev ance Ratne r ALT ANAPharm a ye s 2006a U S NCS Page 111 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Rep o rtingo f attritio n, Lo s s to Au tho r, Allo catio n Gro u p s Eligibility Ou tco me cro s s o v ers , fo llo w-u p : Year, Rando mizatio n co ncealment s imilarat criteria as s es s o rs Carep ro v iderPatient adherence,and differential/ Co u ntry adequ ate? Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Nu mber Clas s Co ntro l Au tho r, Intentio n-to -Po s t- s creened/ naïv e gro u p Year, treat (ITT) rando mizatio n Qu ality eligible/ Ru n-in/ p atients s tandard Co u ntry analys is exclu s io ns rating enro lled Exclu s io ncriteria Was ho u t o nly o f care Ratne r ye s no fair 419/NR/327 Nasalpathologyinc lud ing nasalpolyps7-10d ay no ye s 2006b within 60d aysof stud ye ntry;c linic ally base line run-in U S re le vantre spiratorytrac t m alform ations;re c e ntnasalbiopsy; nasaltraum a;nasalsurge ry;atrophic rhinitis;rhinitism e d ic am e ntosa;ac tive asthm are quiring tre atm e ntwith inhale d or syste m tic c ortic oste roid s; routine use of be taagonists;known hype rse nsitivityto c ortic oste roid s; historyof RT Ior d isord e r within 14 d aysof sc re e ning;tre atm e ntwith syste m ic c ortic oste roid swithin 2 m onthsof stud y;tre atm e ntwith >1% topic alste roid swithin 1m onth of stud y NCS Page 113 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Au tho r, Year, Co u ntry Fu nding Relev ance Ratne r ALT ANAPharm a ye s 2006b U S NCS Page 114 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Rep o rtingo f attritio n, Lo s s to Au tho r, Allo catio n Gro u p s Eligibility Ou tco me cro s s o v ers , fo llo w-u p : Year, Rando mizatio n co ncealment s imilarat criteria as s es s o rs Carep ro v iderPatient adherence,and differential/ Co u ntry adequ ate? Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Nu mber Clas s Co ntro l Au tho r, Intentio n-to -Po s t- s creened/ naïv e gro u p Year, treat (ITT) rando mizatio n Qu ality eligible/ Ru n-in/ p atients s tandard Co u ntry analys is exclu s io ns rating enro lled Exclu s io ncriteria Was ho u t o nly o f care K aise r ye s no fair 428/NR/299 Signific antc onc om itantm e d ic al 5-21d ay no ye s 2007 c ond ition,inc lud ing unc ontrolle d base line run-in U S d ise ase of anybod ysyste m ;se ve re physic alnasalobstruc tion or injury; asthm a;rhinitism e d ic am e ntosa; bac te rialor viralinfe c tion within 2 we e ksof sud ye ntry;ac ute of c hronic sinusitis;glauc om a;c atarac ts;oc ular he rpe ssim ple x;c and id ainfe c tion of the nose ;psyc hiatric d isord e r;ad re nal insuffic ie nc y;use of syste m ic of inhale d c ortic oste roid within 8we e ks of stud ye ntry;use of inhale d NCS within 4we e ksof stud ye ntry;use of othe r m e d ic ationsthatc ould affe c tAR or the e ffe c tive ne ssof the stud yd rug NCS Page 116 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Au tho r, Year, Co u ntry Fu nding Relev ance K aise r GlaxoSm ithK line ye s 2007 R&D U S NCS Page 117 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Rep o rtingo f attritio n, Lo s s to Au tho r, Allo catio n Gro u p s Eligibility Ou tco me cro s s o v ers , fo llo w-u p : Year, Rando mizatio n co ncealment s imilarat criteria as s es s o rs Carep ro v iderPatient adherence,and differential/ Co u ntry adequ ate? Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Nu mber Clas s Co ntro l Au tho r, Intentio n-to -Po s t- s creened/ naïv e gro u p Year, treat (ITT) rando mizatio n Qu ality eligible/ Ru n-in/ p atients s tandard Co u ntry analys is exclu s io ns rating enro lled Exclu s io ncriteria Was ho u t o nly o f care Martin ye s ye s;1/642 fair NR/NR/642 Se ve re physic alobstruc tion of the 5-21d ay no ye s 2007 nose ;re c e ntnasalse ptalsurge ryor base line run-in U S pe rforation;asthm a;rhinitis m e d ic am e ntosa;uppe r RT I;c hronic use of m e d ic ationsthatwould affe c t alle rgic rhinitisor asse ssm e ntsof e ffic ac yof stud ym e d ic ation;c urre nt tobac c o use ;use of subc utane ous om alizum abwithin 5m onthsof stud y; c ortic oste roid s;antihistam ine s; d e c onge stants;intranasal antic holine rgic s;oralantile ukotrie ne s within 3d aysof stud y;intranasalor oc ular c rom olyn within 14d aysof stud y Fokke ns ye s no fair 425/NR/285 Se ve re physic alnasalinjuryor 5-21d ay no ye s 2007 obstruc tion;asthm a;rhinitis base line run-in Europe m e d ic am e ntosa;or anyothe r c hronic m e d ic alc ond ition thatc ould inte rfe re with the c ourse of the stud y;use of INS within 4we e ksof stud y;othe r c ortic oste roid within 8we e ks;any m e d ic ation thatc ould affe c tSAR sym ptom sor e ffe c tive ne ssof stud y m e d ic ation NCS Page 119 of 357 Final Report Update 1 Drug Effectiveness Review Project Ev idenceTable2a. Qu ality o f p lacebo -co ntro lledtrials inp atients withSAR Au tho r, Year, Co u ntry Fu nding Relev ance Martin GlaxoSm ithK line ye s 2007 U S Fokke ns GlaxoSm ithK line ye s 2007 Europe NCS Page 120 of 357 Final Report Update 1 Drug Effectiveness Review Project Eviden ceTable3. Placebo-con trolledtrialsin children withSAR Author Year Coun try Studydesign Allowedothermedication s/ TrialName Settin g Eligibilitycriteria In terven tion s Run -in /WashoutPeriod in terven tion s Ko b a ya shi R a n do m ized, Children a ged 5-13 b eclo m etha so n e Deco n gesta n ts24ho urs R escue m edica tio n : 1989 do ub le-b lin d, yea rs,with sea so n a l dipro pio n a te a queo us b efo re study chlo rhen ira m in e m a lea te 4m g pla ceb o -co n tro lled,a llergic rhin itis n a sa lspra y,42m cg pa ra llel Exclusio n :U se o f twice da ilyvspla ceb o Multicen ter system ic Studydura tio n :3weeks co rtico stero ids, b egin n in g hypo sen sitiza tio n trea tm en t,un derlyin g n a sa lpa tho lo gy,histo ry o fa dverse rea ctio n sto in ha led o rsystem a tic co rtico stero ids, co n curren tvira lin fectio n Strem 1978 R a n do m ized, Children a ged 6-15 flun iso lide n a sa lspra y, NR /NR NR do ub le-b lin d, yea rswith sea so n a l 50m cg three tim esda ily pla ceb o -co n tro lled a llergic rhin itis vspla ceb o Studydura tio n :4weeks NCS Page 121 of 357 Final Report Update 1 Drug Effectiveness Review Project Eviden ceTable3. Placebo-con trolledtrialsin children withSAR Author Number Year Age screen ed/ Coun try Methodofoutcomeassessmen t Gen der Otherpopulation eligible/ Numberwithdrawn / TrialName an dtimin gofassessmen t Ethn icity characteristics en rolled losttofu/an alyzed Ko b a ya shi Eva lua ted a tclin ic o n studyda ys4, Mea n a ge:8. Placebo-con trolledtrialsin children withSAR Author Year Coun try Studydesign Allowedothermedication s/ TrialName Settin g Eligibilitycriteria In terven tion s Run -in /WashoutPeriod in terven tion s G a le 1980 R a n do m ized, Children a ged 5-14 flun iso lide 50m cg fo ur NR /NR NR do ub le-b lin d, yea rswith sea so n a l tim esda ilyvspla ceb o pla ceb o -co n tro lled,a llergic rhin itis Studydura tio n :6weeks pa ra llel Sin gle-cen ter Mun k,1994 R a n do m ized, Children a ged 12-17 In tra n a sa lflutica so n e NR /NR chlo rphen ira m in e m a lea te do ub le-b lin d, yea rswith sea so n a l pro pio n a te 200m cg pla ceb o -co n tro lled,a llergic rhin itis,n a ive to o n ce da ilyvs100m cg pa ra llel in tra n a sa lflutica so n e twice da ilyvspla ceb o Multi-cen ter pro pio n a te,a n d/o rfa iled Studydura tio n :2weeks thera pywith o ther m edica tio n s NCS Page 124 of 357 Final Report Update 1 Drug Effectiveness Review Project Eviden ceTable3.
The impact of treatment with 5-azacytidine followed by donor lymphocyte infusions in chimerism patterns and predonor leukocyte infusion lymphopenia on older patients with acute myeloid leukemia or chronic myelomonocytic survival following T cell-depleted reduced intensity conditioned trans- leukemia relapsed after allografting buy celebrex american express bad arthritis in dogs. Adoptive immunotherapy with cellular therapy following allogeneic hematopoietic stem cell transplan- cytokine-induced killer cells for patients with relapsed hematologic tation for advanced chronic lymphocytic leukaemia buy 100 mg celebrex fast delivery arthritis pain cold weather. Pilot study of prophylactic ex cyte infusion based on chimerism and donor source in pediatric vivo costimulated donor leukocyte infusion after reduced-intensity leukemia order discount celebrex on line arthritis hand surgery. Silberstein2 1Division of Experimental Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; and 2Joint Program in Transfusion Medicine, Children’s Hospital Boston, Boston, MA In blood, oxygen is transported principally by hemoglobin tetrameric molecules in erythocytes, which allow for the delivery to tissue cells. When anemia occurs, such as perisurgically or after trauma, blood transfusion is administered to replace the deﬁcit in oxygen-carrying capacity. During embryogenesis and later in adult life, tissue oxygen levels control multiple key cellular functions. Low tissue oxygen levels in particular are physiologically relevant to stem cells by controlling their metabolism and cell fate. In adult life, hematopoietic stem cells reside in speciﬁed BM microenvironments/niches, where their quiescence and differentiation are presumably also inﬂuenced by cell-intrinsic and cell-extrinsic (niche) factors. Novel imaging technologies have allowed determination of the spatial localization of hematopoietic stem/progenitor cells (HSPCs), as well as the topography of oxygen distribution in BM cavities. Together, these recent advances have contributed to the emergence of a novel model that challenges the previous concept of a hypoxic hematopoietic stem cell niche characterized by poorly perfused endosteal zones with the deepest hypoxia. HSPCs display a hypoxic phenotype despite residing in close association with arterial or sinusoidal vascular networks. The entire BM cavity is hypoxic and unexpectedly exhibits an opposite oxygen gradient to the one initially proposed because arteriole-rich endosteal zones are relatively less hypoxic than deeper regions of the BM perfused by dense sinusoidal networks. Therefore, further studies are warranted to elucidate to what extent differences in oxygen tensions in these diverse microenvironments inﬂuence HSPC homeostasis. At a molecular level, ● To understand the fundamental basic research carried out to hypoxic conditions lead to the induction of many well-characterized investigate the relevance of hypoxic conditions in bone intracellular signaling pathways, including the ones elicited by marrow microenvironments that support hematopoietic stem hypoxia-inducible transcription factors (HIFs), which inﬂuence cell maintenance numerous cell functions related to the preservation of stem cell identity, quiescence, and the metabolic shift toward anaerobic Oxygen in tissues and stem cell biology glycolysis. During evolution, ﬂuctuations in atmospheric oxygen concentration have deﬁned eukaryotic life forms on earth, exempliﬁed by the Hematopoiesis: a paradigm to study tissue stem adoption of efﬁcient oxidative phosphorylation (ie, aerobic metabo- cell–based maintenance lism) to support more complex and multicellular organisms. Therefore, proper tissue exceptionally large numbers of relatively short-lived mature blood function strictly relies on the constant delivery of adequate oxygen cells, which can rapidly increase in response to enhanced demand levels to all cellular environments in the organism. Physiologic during stress conditions such as bleeding and infections. Whereas some tissues, such as the lung, liver, and heart, gained regarding the multistep stem cell differentiation process and have relatively higher partial pressures of oxygen (pO2), others, its regulation by transcription factor pathways. However, only such as the BM, brain, and eye, are relatively more hypoxic (Figure recently are the tools being developed to investigate the speciﬁc 1). The concept of a hematopoietic stem cell (HSC) niche was proposed almost 40 years ago as an anatomically conﬁned microen- Therefore, even in homeostatic conditions, oxygen levels may be as vironment in the BM that uniquely controls HSPC quiescence, low as 1% in certain tissue microenvironments or niches in which self-renewal, and differentiation. Indeed, in the past decade, a growing body of evidence has signals from adjacent cells, extracellular matrix, and soluble growth supported the idea that local maintenance of relatively low pO is factors. The and/or near vascular structures with limited perfusion. However, physiological implications of such histological observations have evidence in support of this model has been indirect and inconclu- typically been conﬁrmed by assessing the effects that perturbations sive. Recent studies have sought to further deﬁne the metabolic of either the functionality or the numbers of candidate niche cells and/or hypoxic phenotype of HSPCs in the context of their spatial exert directly on the number and function of HSPCs. These distribution and cellular associations within distinct zones of the strategies have yielded signiﬁcant advances in our understanding of BM cavity. In the following sections, we discuss recent ﬁndings that HSPC cellular associations, which have been extensively reviewed have led to an emerging view regarding the role of microenvironmen- in recent publications to which we refer the reader. In brief, initial studies, which used mostly ex vivo puriﬁed, HIF-1 protein expression ﬂuorescently labeled adoptively transferred cells or label-retaining In tumors and in some organs, oxygen gradients exist that allow methods to detect quiescent HSPCs, highlighted the importance of tissue cells to adapt to hypoxic environments/niches as low as 1%. Nonetheless, using simpliﬁed phenotypic combina- regulated by intracellular oxygen levels. When oxygen pressures tions to track endogenous HSPCs, multiple groups have now shown increase above certain levels ( 5%), HIF-1 becomes hydroxy- that HSPCs are scattered in perivascular locations and in contact lated and is targeted for ubiquitinylation and degradation in the with a variety of stromal cell subsets of mesenchymal and neural proteasome. This heterodimer binds to hypoxia response element quiescent state, presumably regulated by the niches in which they sequence domains on multiple chromosomes, leading to the activa- reside. A prevailing model applied to stem cells and tumor stem tion of a broad transcriptional program that includes 100 genes cells hypothesized that induction into quiescence is, at least partially involved in survival, proliferation, neovascularization, and cell cycle. The resultant metabolic state is necessary for HSC homeostasis and self-renewal potential (Figure 2). A functional link between stemness and reduced oxygen availability Hypoxyprobe pimonidazole has been in fact reported for multiple stem cell types and extensively Pimonidazole (Pimo) is the most widely used and extensively studied in the case of HSPCs. In the absence/ hypoxia could be a hallmark of the native tissue context in which deﬁcit of intracellular oxygen, Pimo becomes increasingly reduced, HSPCs are preserved. Protein adducts of reduced for intracellular hypoxia (pimonidazole),19 as well as the stable Pimo are in turn potent immunogens that can be detected using expression and functional role of HIF in primitive hematopoietic enzymatically or ﬂuorescently labeled polyclonal and monoclonal populations20 (discussed in detail in the following section). Based antibodies and therefore quantiﬁed in ﬂow cytometry or micros- on these data, it was speculated that quiescent and self-renewing copy techniques. Therefore, Pimo incorporation is a consequence Hematology 2014 543 Figure 2. At low oxygen levels, HIF-1 protein is stable, heterodimerizes, and translocates to the nucleus. At higher oxygen levels, HIF-1 is hydroxylated and targeted to the proteasome. For these properties, Pimo had been broadly used as a zones (not restricted to bone-lining areas and deﬁned by 100 m), surrogate marker of low intracellular oxygen availability in solid gradually decreasing toward bone distal areas. Subsequent studies aimed at understanding oxygenation imaging of sternal bones, Kunisaki et al observed similar patterns of dynamics in the BM demonstrated that HSPCs were among the HSPC distribution with regard to bone surfaces,15 a spatial proﬁle cellular fraction of the BM that contained the highest levels of Pimo comparable to the one described for progenitor cells in human BM adducts 90 minutes after intraperitoneal administration of Pimo, as and humanized mouse models. Given the strong experimental evidence suggesting a close areas of the BM with minimal oxygenation (Figure 3). Consistent with an earlier study,26 within the diaphysis of the BM, large nutrient arteries run makeup of these regulatory entities. Until recently, a comprehensive analysis of HSPC localization in BM had not been feasible, leaving longitudinally throughout the length of the cavity, splitting into open the question of whether HSPC frequencies would still be smaller arteries that migrate outwardly toward the inner margins of higher in deﬁned districts within the BM cavity. As they approach the endosteum, arterial branches give have addressed this issue and reached comparable results. Along the surface of the endosteum, arterioles quantitative imaging cytometry to analyze entire whole longitudinal transition into sinusoidal microvessels, which constitute the venous equivalent of BM circulation and exhibit unique morphological and functional features (Figure 4). Sinusoids spatially arrange as a honeycomb-like network of large, wide vessels that form frequent anastomoses and migrate radially to merge into a central sinus into which BM diaphyseal circulation drains. As for the diaphysis within trabecular bone regions, arterial to sinusoidal transitions were mostly observed along en- Figure 3. Similar immunohistological approaches have been nitroimidazole molecules compete with oxygen for electrons that are used by different groups to study the 3D organization of microvas- generated by oxidative phosphorylation. In the absence of oxygen or in cular compartments in tibial, sternal and calvarial BM cavi- the presence of an insufﬁcient amount of oxygen, nitroimidazoles such as ties. Within a longitudinal view of the diaphysis, ascending and descending medullary arteries branch out to give rise to radial arteries.
Severe diarrhea and cho- lesterol elevations occurred at the same frequency purchase celebrex 200 mg with amex arthritis of the shoulder. In treatment-experienced patients in the CONTEXT study cheap 200mg celebrex overnight delivery arthritis in dogs drugs, fosamprenavir was not quite as effective as lopinavir/r although the difference was not significant (Elston 2004) cheap 100mg celebrex with mastercard rheumatoid arthritis numbers. Fosamprenavir currently does not play an important role in HIV medicine. One advantage of the drug is that there are no restrictions with respect to food intake. It is important to note that efavirenz can significantly lower plasma levels, as can nevirapine, although this does not occur when fosamprenavir is boosted (Elston 2004). Indinavir (IDV, Crixivan) was one of the first PIs, initially very successful in large studies (Gulick 1997, Hammer 1997). Firstly, it causes nephrolithiasis in 5–25% (Meraviglia 2002) and thus requires good hydration (at least 1. Unboosted indinavir must be taken three times daily on an empty stomach (Haas 2000). When boosted at 2 x 800/100 mg, tolerability is poor. Side effects resemble those of retinoid therapy: alopecia, dry skin and lips, and ingrown nails. Many patients also develop asymptomatic hyperbilirubinemia. Although it seems that the dose and toxicity can be reduced by TDM (Wasmuth 2007), indinavir does no longer play a role. Lopinavir/r (LPV, Kaletra) was licensed in April 2001 and is so far the only PI with a fixed boosting dose of ritonavir. This increases concentrations of lopinavir by more than 100-fold (Sham 1998). In 2006, the old Kaletra capsules were replaced by tablets, allowing a pill reduction (Gathe 2008). Lopinavir is still the most frequently prescribed PI worldwide and has also been licensed as once-daily since 2009 after several studies showed efficacy and tolerability (Molina 2007, Gathe 2009, Gonzalez- Garcia 2010). However, other studies found a slightly reduced potency of QD dosing 6. Overview of antiretroviral agents 95 (Ortiz 2008, Flexner 2010). Lopinavir QD is therefore only recommended if the number of PI resistance mutations is low. In treatment-naïve patients, lopinavir/r was significantly superior to an unboosted regimen with nelfinavir (Walmsley 2002). However, more recently, large randomized trials such as KLEAN, GEMINI, ARTEMIS and CASTLE have shown that there are no significant differences compared to boosted PIs such as fosamprenavir/r (Eron 2006), saquinavir/r (Walmsley 2009), or atazanavir/r (Molina 2008). In ACTG 5142, lopinavir/r was inferior to efavirenz (Riddler 2008), possibly due to lower tolerability. In treatment-experienced patients, lopinavir/r showed slightly better results than boosted saquinavir (the old Fortovase formulation) in an open-label randomized trial (MaxCmin2) on a heterogeneous population of treatment-experienced patients. This was particularly true for tolerability, but also with respect to treatment failure (Dragstedt 2005). On the other hand, in two smaller studies in PI-experienced patients, virologic efficacy of lopinavir/r was not significantly higher than that of boosted atazanavir (Johnson 2006) or fosamprenavir (Elston 2004). In comparison to darunavir, efficacy was even lower (Madruga 2007, De Meyer 2009). Development of resistance in first-line is rare, but is theoretically possible (Kagan 2003, Conradie 2004, Friend 2004). Lopinavir/r has a high genetic barrier to resistance, and it is likely that at least 6-8 cumulative PI resistance mutations are necessary for treatment failure (Kempf 2002). That is why lopinavir is also considered for monotherapies (see below). A significant concern with lopinavir are the gastrointestinal side effects (diarrhea, bloating) which are probably more frequent on a once-daily dosage (Johnson 2006). In addition, lipodystrophy and often considerable dyslipidemia, have been observed, probably more marked than with atazanavir (Molina 2008, Mallolas 2009), darunavir (Mills 2009) and saquinavir (Walmsley 2009), but not more so than with fosampre- navir (Eron 2006). The dose must be increased in combination with efavirenz and nevirapine, probably also with concurrent administration of fosamprenavir. Nelfinavir (NFV, Viracept) was the fourth PI on the market. Due to high pill burden, diarrhea and a lower antiviral potency, nelfinavir no longer plays much of a role in HIV treatment. Ritonavir (RTV, Norvir) was the first PI for which efficacy was proven on the basis of clinical endpoints (Cameron 1998). However, ritonavir is now obsolete as a single PI, since tolerability is poor. As gastrointestinal complaints and perioral paresthesias can be very disturbing, ritonavir is now only given to boost other PIs. The “baby dose” used for this purpose (100 mg QD) is better-tolerated. Ritonavir inhibits its own metabolism via the cytochrome P450 pathway. The potent enzyme induction results in a high potential for interactions. Many drugs are contraindicated for concomitant administration with ritonavir. Metabolic disorders probably occur more frequently than with other PIs. Caution should be exercised in the presence of impaired liver function. It is no longer necessary to store ritonavir at cool tempera- tures thanks to the Meltrex formulation that came onto the market in 2010. Saquinavir (Invirase 500), previously Invirase, Fortovase, was the first HIV PI to be licensed in December 1995, and is still one of the few agents with efficacy based on clinical endpoints (Stellbrink 2000). Boosting with ritonavir raises the plasma level sufficiently, as does simultaneous food intake, so saquinavir should be taken with meals. The hard gel (Invirase) and soft gel (Fortovase) capsules were replaced in 2005 by Invirase 500 tablets, which significantly reduced the number of pills to six a day (including ritonavir boosting). The GEMINI trial compared ritonavir- 96 ART boosted Invirase 500 tablets to lopinavir/r in 330 ART-naïve patients who all received TDF+FTC. There were no significant differences with respect to efficacy at 48 weeks (Walmsley 2009). Some adverse effects such as lipid elevations were less pronounced with saquinavir, as was diarrhea.
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes purchase celebrex 100mg rheumatoid arthritis headache. Diabetic medicine : a journal of the British Diabetic Association generic 100mg celebrex amex arthritis relief cold or hot. Sharma PK buy 200 mg celebrex amex arthritis pain relief elbow, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. Thiazolidinediones Page 101 of 193 Final Report Update 1 Drug Effectiveness Review Project 141. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Hanefeld M, Patwardhan R, Jones NP, Rosiglitazone Clinical Trials Study G. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition, metabolism, and cardiovascular diseases : NMCD. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Davidson JA, Perez A, Zhang J, The Pioglitazone 343 Study G. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic medicine : a journal of the British Diabetic Association. Thiazolidinediones Page 102 of 193 Final Report Update 1 Drug Effectiveness Review Project 156. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Rosiglitazone-associated fractures in type 2 diabetes. Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Allocation concealment: The process by which the person determining randomization is blinded to a study participant’s group allocation order celebrex now arthritis in neck with headaches. Applicability: see External Validity Before-after study: A type nonrandomized study where data are collected before and after patients receive an intervention cheap celebrex online amex arthritis pain relief gel. Before-after studies can have a single arm or can include a control group cheap 200mg celebrex mastercard arthritis pain night legs. Bias: A systematic error or deviation in results or inferences from the truth. Several types of bias can appear in published trials, including selection bias, performance bias, detection bias, and reporting bias. Bioequivalence: Drug products that contain the same compound in the same amount that meet current official standards, that, when administered to the same person in the same dosage regimen result in equivalent concentrations of drug in blood and tissue. Black box warning: A type of warning that appears on the package insert for prescription drugs that may cause serious adverse effects. It is so named for the black border that usually surrounds the text of the warning. A black box warning means that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects. The US Food and Drug Administration (FDA) can require a pharmaceutical company to place a black box warning on the labeling of a prescription drug, or in literature describing it. Blinding: A way of making sure that the people involved in a research study — participants, clinicians, or researchers —do not know which participants are assigned to each study group. Blinding usually is used in research studies that compare two or more types of treatment for an illness. Disease-modifying drugs for multiple sclerosis Page 98 of 120 Final Report Update 1 Drug Effectiveness Review Project Case series: A study reporting observations on a series of patients receiving the same intervention with no control group. Case study: A study reporting observations on a single patient. Case-control study: A study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls). Clinical diversity: Differences between studies in key characteristics of the participants, interventions or outcome measures. Clinically significant: A result that is large enough to affect a patient’s disease state in a manner that is noticeable to the patient and/or a caregiver. Cohort study: An observational study in which a defined group of people (the cohort) is followed over time and compared with a group of people who were exposed or not exposed to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective cohort study identifies subjects from past records and follows them from the time of those records to the present. Combination Therapy: The use of two or more therapies and especially drugs to treat a disease or condition. Confidence interval: The range of values calculated from the data such that there is a level of confidence, or certainty, that it contains the true value. The 95% confidence interval is generally used in Drug Effectiveness Review Project reports. If the report were hypothetically repeated on a collection of 100 random samples of studies, the resulting 95% confidence intervals would include the true population value 95% of the time. Confounder: A factor that is associated with both an intervention and an outcome of interest. Controlled clinical trial: A clinical trial that includes a control group but no or inadequate methods of randomization. Control group: In a research study, the group of people who do not receive the treatment being tested. The control group might receive a placebo, a different treatment for the disease, or no treatment at all. Convenience sample: A group of individuals being studied because they are conveniently accessible in some way. Convenience samples may or may not be representative of a population that would normally be receiving an intervention. Crossover trial: A type of clinical trial comparing two or more interventions in which the participants, upon completion of the course of one treatment, are switched to another. Direct analysis: The practice of using data from head-to-head trials to draw conclusions about the comparative effectiveness of drugs within a class or group. Results of direct analysis are the preferred source of data in Drug Effectiveness Review Project reports. Dosage form: The physical form of a dose of medication, such as a capsule, injection, or liquid. The route of administration is dependent on the dosage form of a given drug. Various dosage forms may exist for the same compound, since different medical conditions may warrant different routes of administration. Dose-response relationship: The relationship between the quantity of treatment given and its effect on outcome. In meta-analysis, dose-response relationships can be investigated using meta- regression. Double-blind: The process of preventing those involved in a trial from knowing to which comparison group a particular participant belongs. While double-blind is a frequently used term Disease-modifying drugs for multiple sclerosis Page 99 of 120 Final Report Update 1 Drug Effectiveness Review Project in trials, its meaning can vary to include blinding of patients, caregivers, investigators, or other study staff. Double-dummy: The use of two placebos in a trial that match the active interventions when they vary in appearance or method of administrations (for example, when an oral agent is compared with an injectable agent). Effectiveness: The extent to which a specific intervention used under ordinary circumstances does what it is intended to do. Effectiveness outcomes: Outcomes that are generally important to patients and caregivers, such as quality of life, responder rates, number and length of hospitalizations, and ability to work. Data on effectiveness outcomes usually comes from longer-term studies of a “real-world” population. Effect size/estimate of effect: The amount of change in a condition or symptom because of a treatment (compared to not receiving the treatment). It is commonly expressed as a risk ratio (relative risk), odds ratio, or difference in risk. Efficacy: The extent to which an intervention produces a beneficial result under ideal conditions in a selected and controlled population. Equivalence level: The amount which an outcome from two treatments can differ but still be considered equivalent, as in an equivalence trial, or the amount which an outcome from treatment A can be worse than that of treatment B but still be considered noninferior, as in a noninferiority trial.